VolitionRX Limited (VNRX)
| Market Cap | 140.54M |
| Revenue (ttm) | 178,716 |
| Net Income (ttm) | -28.33M |
| Shares Out | 53.85M |
| EPS (ttm) | -0.51 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 48,803 |
| Open | 2.70 |
| Previous Close | 2.70 |
| Day's Range | 2.56 - 2.70 |
| 52-Week Range | 2.08 - 4.14 |
| Beta | 1.72 |
| Analysts | Buy |
| Price Target | 7.75 (+196.9%) |
| Earnings Date | May 12, 2022 |
About VNRX
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texa...
Financial Performance
In 2021, VolitionRX's revenue was $90,035, an increase of 570.25% compared to the previous year's $13,433. Losses were -$26.81 million, 31.8% more than in 2020.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for VNRX stock is "Buy." The 12-month stock price forecast is 7.75, which is an increase of 196.93% from the latest price.
News
VolitionRx Limited Announces First Quarter 2022 Financial Results and Business Update
Conference call to discuss financial and operational results scheduled for Thursday, May 12, at 8:30 a.m. U.S. Eastern Time AUSTIN, Texas, May 11, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN:...
VolitionRx Limited Schedules First Quarter 2022 Earnings Conference Call and Business Update
Conference call to take place on Thursday May 12 at 08:30 a.m. Eastern Time Capital Markets Day Friday May 13 at 10:00 a.m.
VolitionRx Limited to Host Capital Markets Day on Friday May 13
AUSTIN, Texas , May 5, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") a multi-national epigenetics company plans to host a Capital Markets Day in a hybrid format on Friday, ...
Volition Launches its Nu.Q® Vet Cancer Test in Asia Through its Appointed Distributor SAGE Healthcare
AUSTIN, Texas , April 25, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to h...
Volition appoints Sharon Ballesteros as U.S. Head of Quality and Development Process
AUSTIN, Texas , April 6, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced the appointment of Sharon Ballesteros as U.S Head...
VolitionRx Limited Announces Full Fiscal Year 2021 Financial Results and Business Update
Conference call to discuss financial and operational results scheduled for Thursday, March 31, at 8:00am U.S. Eastern Time · Executed global licensing and supply agreement with Heska Corporation ...
Heska Corporation Signs Exclusive Agreement to Introduce Nu.Q® Vet Cancer Screening Test, First-Ever Point of Care Ca...
LOVELAND, Colo. , March 29, 2022 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA) ("Heska"), a leading global provider of advanced veterinary diagnostics, has announced an exclusive global supply and li...
Volition Signs Exclusive $28 million License and Supply Agreement with Heska Corporation to Distribute Nu.Q® Vet Canc...
AUSTIN, Texas, March 29, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced the signing of an exclusive global supply and lic...
VolitionRx Limited Schedules Full Fiscal Year 2021 Earnings Conference Call and Business Update
Conference call to take place on Thursday March 31 at 08:00a.m. Eastern time AUSTIN, Texas, March 28, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will h...
Volition presents study data at ASCO GI 2022 on circulating nucleosomes for the detection of colorectal cancer and hi...
AUSTIN, Texas, Jan. 20, 2022 /PRNewswire/ --VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced the results of two large scale clinical studies, wh...
Volition Executes its First Supply and Licensing Contract for its Nu.Q® Vet Cancer Screening Test in Asia
SAGE Healthcare Private Limited appointed to serve as a non-exclusive licensee and distributor for Volition's Nu.Q® Vet Cancer Screening Test in centralized labs in Singapore, with launch planned in Sin...
VolitionRx Limited Announces Third Quarter 2021 Financial Results and Business Update
Conference call to discuss financial and operational results scheduled for Thursday, November 11, at 8:00 a.m. U.S. Eastern Time Healthy balance sheet with approximately $22.9 million in cash and cash e...
VolitionRx Limited Schedules Third Quarter 2021 Earnings Conference Call and Business Update
AUSTIN, Texas, Nov. 8, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Thursday, November 11, at 8:00 a.m. Eastern time to di...
Volition Veterinary Presents Two Posters at the 2021 Veterinary Cancer Society Conference
Positive data show Nu.Q® can be used to monitor for disease response and progression including remission monitoring in cancer bearing dogs. Paves the way for second Nu.Q® Vet product launch planned for ...
VolitionRx Limited Announces Second Quarter 2021 Financial Results and Business Update
Strong balance sheet with approximately $27.9 million in cash and cash equivalents Strengthened the Company's veterinary leadership team to drive commercial focus Expanded the Company's intellectual pro...
VolitionRx Limited Schedules Second Quarter 2021 Earnings Conference Call and Business Update
AUSTIN, Texas, Aug. 4, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Thursday, August 12, at 8:00 a.m. Eastern time to disc...
Volition's Nu.Q® NETs Assay Demonstrates Promising Results in COVID-19 Risk Stratification and Disease Monitoring
AUSTIN, Texas, July 22, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to hel...
VolitionRx Limited Announces First Quarter 2021 Financial Results and Business Update
Secured strongest-ever balance sheet with approximately $33.1 million in cash Strengthened the Company's leadership team to drive commercial focus Expanded the Company's intellectual property portfolio ...
VolitionRx Limited Schedules First Quarter 2021 Earnings Conference Call and Business Update
AUSTIN, Texas, May 6, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Wednesday May 12, at 8:00 a.m. Eastern time to discuss ...
VolitionRx Limited Announces Publication of Significant Nu.Q® Capture Mass Spectrometry Paper
AUSTIN, Texas, March 31, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to he...
VolitionRx Limited Appoints Dr. Tom Butera DVM as Chief Executive Officer for Volition Veterinary Subsidiary
AUSTIN, Texas, March 30, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to he...
VolitionRx Limited Appoints Two New Directors
AUSTIN, Texas, March 29, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to he...
VolitionRx Limited Announces Full Fiscal Year 2020 Financial Results and Business Update
Launched first product, the Nu.Q® Vet Cancer Screening Test and recorded first revenue from sales of a commercial product Engaged Diagnostic Oncology CRO LLC to conduct U.S. regulatory clinical trial fo...
New Data Demonstrates Nu.Q® is Effective in Monitoring Treatment of Sepsis
AUSTIN, Texas, March 17, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to he...
VolitionRx Limited Schedules Full Fiscal Year 2020 Earnings Conference Call and Business Update
AUSTIN, Texas, March 16, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Tuesday, March 23, at 8:00 a.m. Eastern time to disc...